<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00816452</url>
  </required_header>
  <id_info>
    <org_study_id>RISED_L_04261</org_study_id>
    <nct_id>NCT00816452</nct_id>
  </id_info>
  <brief_title>Awareness to Osteopenia's Treatment by Bisphosphonate in Male Suffering From Prostate Cancer</brief_title>
  <acronym>InoPro</acronym>
  <official_title>Title: Increase Awareness to Osteopenia/Osteoporosis Treatment of Patients With Prostate Cancer, by Bisphosphonate Therapy - Registry.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <brief_summary>
    <textblock>
      Patients with prostate cancer treated in outpatient clinics will be recruited by their
      urologist physician.

      Primary Objective: To evaluate the compliance in male patients with prostate cancer treated
      with Bisphosphonate and that suffered from Osteopenia/osteoporosis.

      Secondary objectives:

      To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon
      recommendation by Urologists.

      To evaluate the overall number of patients treated by Bisphosphonate in the out-patient
      clinics, To evaluate incidence of osteopenia/osteoporosis in this study population.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the compliance in male patients with prostate cancer treated with Bisphosphonate and that suffered from Osteopenia/osteoporosis.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the compliance of family physicians to prescribe Bisphosphonate for patients upon recommendation by Urologists.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the overall number of patients treated by Bisphosphonate in the out-patient clinics</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate incidence of osteopenia/osteoporosis in this study population.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">180</enrollment>
  <condition>Osteoporosis</condition>
  <condition>Prostate Cancer</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Male with Prostate Cancer suffering from Osteoporosis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Man with Prostate Cancer

          -  Men ≥70 years old or ≥60 years old treated by LH-RH agonist for at least 2 years or
             Man who was diagnosed in the past with Osteopenia/osteoporosis

          -  Osteopenia/osteoporosis proven by bone density test.

        Exclusion Criteria:

          -  Creatinine clearance &lt; 30ml/min

          -  Hypercalcemia

          -  Actual treatment by Bisphosphonate or steroids

          -  Hypersensibility to Bisphosphonate or any contraindication to its use.

          -  Metastatic prostate Cancer

          -  Patients not suitable for compliance.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nurit Tweezer</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi-aventis administrative office Israel</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis administrative office</name>
      <address>
        <city>Natanya</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>November 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 31, 2008</study_first_submitted>
  <study_first_submitted_qc>December 31, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 1, 2009</study_first_posted>
  <last_update_submitted>November 2, 2010</last_update_submitted>
  <last_update_submitted_qc>November 2, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 3, 2010</last_update_posted>
  <responsible_party>
    <name_title>Trial Transparency Team</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <keyword>Osteoporosis</keyword>
  <keyword>Prostate Cancer</keyword>
  <keyword>Osteoporosis in male with Prostate Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
    <mesh_term>Osteoporosis</mesh_term>
    <mesh_term>Bone Diseases, Metabolic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diphosphonates</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

